# Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

> **NCT00348881** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 2133 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Influenza

## Interventions

- **BIOLOGICAL:** DTaP-HB-PRP~T combined vaccine
- **BIOLOGICAL:** Tritanrix-HepB/Hib™ vaccine
- **BIOLOGICAL:** Oral poliomyelitis vaccine (OPV)

## Key facts

- **NCT ID:** NCT00348881
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-10
- **Final completion:** 2008-06
- **Target enrollment:** 2133 (ACTUAL)
- **Last updated:** 2013-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348881, "Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00348881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*